Published Online: 2025 January 7

Research Article



A Longitudinal Study of Point Prevalence of Antimicrobial Use and Resistance in Ahvaz Hospitals in 2020 - 2021: A Multicenter Study

Ahmad Shamsizadeh (b)¹, Shideh Assar (b)², Jafar Soltani (b)³, Mohammad Reza Aramesh (b)⁴, Mohammad Reza Fathi (b)⁵, Fereshteh Shakournia (b)⁶, Mostafa Pakmehr (b)⁶, Hossein Ghaedamini (b)⁶,*

¹ Department of Pediatrics, Infectious and Tropical Diseases Research Center, Health Research Institute, Abouzar Hospital, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

² Department of Pediatrics, Golestan Hospital, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

³ Department of Pediatrics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

⁴ Department of Pediatrics, Imam Khomeini Hospital, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

⁵ Department of Pediatrics, Abouzar Hospital, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

⁶ Department of General Surgery, Imam Khomeini Hospital, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

* Corresponding Author: Department of General Surgery, Imam Khomeini Hospital, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: ghaedaminih@gmail.com

Received: 17 August, 2024; Revised: 14 December, 2024; Accepted: 24 December, 2024

Abstract

Background: Excessive prescription of antibiotics is the main factor contributing to the emergence of resistant bacteria.

Objectives: To complement the global research conducted by Belgium's Antrop University and the World Health Organization (WHO) in Iran, this study aimed to evaluate the prevalence of antibiotic prescriptions in Ahvaz hospitals.

Methods: This was a descriptive longitudinal study. The statistical population consisted of all patients hospitalized at Imam Khomeini, Golestan, and Abuzar Hospitals in Ahvaz between 2020 and 2021 (2035 patients). The data collection tool was a checklist from the educational department and special care department, completed by clinical assistants and recorded in the Global Point Prevalence online software. Data analysis was performed using SPSS version 22.

Results: The overall prevalence of antimicrobial use in Golestan, Imam Khomeini, and Abuzar Hospitals was reported as 43.2%, 44.1%, and 57.9%, respectively. The most common antibiotics for treating sepsis in both adults and children were vancomycin and meropenem. The most commonly used antibiotics for treating upper and lower urinary tract infections (UTIs) and for surgical prophylaxis were ceftriaxone and meropenem. Meropenem was the most commonly used antibiotic for treating pneumonia. The highest rates of antimicrobial resistance were reported for cefazolin (81.42%), ampicillin (93.77%), and ampicillin (94.02%) in Golestan, Imam Khomeini, and Abuzar Hospitals, respectively. The lowest rates of antimicrobial resistance were reported for ciprofloxacin (18.57%) in Golestan Hospital, ciprofloxacin (15.58%) in Imam Khomeini Hospital, and piperacillin/tazobactam (12.04%) in Abuzar Hospital.

Conclusions: Due to the high consumption of ceftriaxone and the significant resistance to ampicillin and cefazolin, continuous monitoring is essential to adjust antibiotic usage and resistance patterns in local, provincial, and national referral hospitals.

Keywords: Prevalence, Drug Resistance, Anti-bacterial Agents, Iran

1. Background

Bacterial infections resistant to available antibiotics have become a major health problem worldwide. These infections are severe, requiring expensive diagnostic methods and prolonged treatments (1, 2). Antibiotic resistance is a global and increasing threat to human health, with excessive use of antibiotics being one of the primary causes (2-5). Antibiotic resistance depends on both the quantity and inappropriate use of antibiotics. It remains unclear why antibiotic resistance is spreading rapidly in developing countries (6). The role

Copyright © 2025, Shamsizadeh et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

of factors such as administering antibiotics to promote growth in livestock, the release of antibiotics into urban wastewater by pharmaceutical manufacturers, or poor hygiene practices is not well understood (7).

In European countries, particularly in Scandinavian nations where antibiotic use is lower, antibiotic resistance is also lower (4, 8). Antibiotic resistance is associated with healthcare-associated infections (9). Strategies to control antibiotic use, including limiting antibiotic prescriptions and providing proper education, have significantly impacted the reduction of antibiotic prescriptions (10). Without mandatory guidelines, physicians are often hesitant to shorten the prescription period or limit their empirical antibiotic choices (5). Studies in Europe and the United States have shown that limiting antibiotic use was implemented correctly in only 11 - 55% of patients (5, 10, 11). Several potential options exist to moderate antibiotic prescriptions and reduce antibiotic resistance (2, 5). In recent years, measures have been introduced to improve antibiotic administration in hospitals (12). Providing evidence for antibiotic prescriptions, rotating antibiotics, and combining antibiotic therapies have been suggested as strategies to reduce antibiotic resistance, although the use of these methods has limitations (3).

The global point prevalence survey of antimicrobial consumption and resistance (GLOBAL-PPS 2020) was conducted under the management of Antwerp University, Belgium, with the aim of improving the prescription of antibiotics in hospitalized patients. This project focuses on collecting data on antibacterials, systemic antivirals, antibiotics used in the treatment of tuberculosis, and antibiotics used for intestinal infections in European hospitals and volunteer countries (13). Another important goal of this standard monitoring is to gather data from all European Union countries and other participating nations (73 countries) to track the use of antimicrobial agents in patients across all age groups. Additionally, the World Health Organization (WHO) provided support and solutions to help control and improve the process of antibiotic prescription and manage antibiotic resistance (5). This program identifies the type, dosage, and indications for prescribing antibiotics in hospitalized patients.

2. Objectives

Given that excessive antibiotic prescription is a primary factor in the emergence and spread of resistant bacteria, we have chosen to conduct a longitudinal study in collaboration with the University of Antwerp in Belgium and the WHO. Our objective is to investigate the prevalence of both general and inappropriate antibiotic prescriptions, as well as to evaluate antibiotic resistance in Ahvaz, a city located in the southwest of Iran.

3. Methods

This study was a descriptive longitudinal study conducted on all patients hospitalized in Imam Khomeini, Golestan, and Abuzar (pediatric center) Hospitals of Ahvaz University of Medical Sciences between 2020 and 2021, with a total of 2,035 participants. The study evaluated forty-three hospital wards across the three hospitals using a census method. Inclusion criteria required participants to have received systemic antibiotics and been hospitalized before 8 AM on the day of the study. Data for each hospital were collected over four consecutive weeks, including cases where antimicrobials were prescribed for at least 48 hours, even if discontinued on the day of data collection. Any antimicrobial use that began after the afternoon of the data collection day was excluded from the study.

During the study, information from each ward was collected separately on a specific day. The data collection tool used was checklists. Participants' demographic information, such as age, gender, weight, and specific details including the type of antimicrobial medicines, dosage per administration, number of doses per day, method of administration, main diagnosis, and anatomical site of infection or reason for prophylaxis, were collected according to a list of treatment indications (community-acquired infections, hospitalacquired infections, or prophylaxis). Data collection was guided by the project manager at Antwerp University, Belgium, using internet resources. Information for all hospitalized patients was gathered, with data from each hospital entered into the checklist over a two-week period. This information was then recorded in the online software specific to this study (Global Point Prevalence software).

According to the GLOBAL, antibiotic usage is classified as follows (13):

- Hospitals: Golestan, Imam Khomeini, Abuzar

- Country: Iran
- Continent: East and South Asia

- Hospital type: Tertiary hospitals (major hospitals that typically offer a full range of services, including pediatrics, obstetrics, general medicine, gynecology, various branches of surgery, psychiatry, or specialty hospitals dedicated to specific sub-specialties such as pediatric centers, oncology centers, or psychiatric hospitals. Patients are often referred from smaller hospitals to tertiary hospitals for major surgeries, consultations with sub-specialists, or when advanced intensive care facilities are required).

- Region: Europe

Throughout the study, there was no discussion or personal judgment regarding the appropriateness of antibiotic prescriptions. Statistical analysis was performed by comparing the results with those from other countries. Continuous quantitative variables, such as the mean and standard deviation, were calculated, while qualitative variables were reported as numbers and percentages. The data were analyzed using SPSS 22 and Excel 2016 software.

4. Results

This study was conducted with 2035 participants, of whom 50.51% were male. A total of 41.22% of the participants were from Imam Khomeini Hospital (Table 1). The results showed that the overall frequency of antibacterial use in Golestan and Imam Khomeini Hospitals was 338 (43.2%) and 370 (44.1%), respectively. This rate was reported as 216 (57.9%) in the children's general ward and 36 (86.1%) in the pediatric intensive care unit (PICU) at Abuzar Hospital. Additionally, in this hospital, the frequency of children who received at least one dose of antimicrobial medicine per day was 81 (21.6%) (Table 2).

The overall frequency of antibacterial use in adults at Golestan and Imam Khomeini Hospitals was 151 (31.1%) and 104 (27.9%), respectively. In the surgical wards of Golestan and Imam Khomeini Hospitals, the frequency was 116 (56%) and 25 (52%), respectively. In the intensive care units (ICU) of these hospitals, the frequency was 71 (47.9%) and 187 (40.6%), respectively. In the pediatric wards of these hospitals, the frequency was 19 (10.5%) and 60 (71.7%), respectively (Table 2).

The most commonly used antibiotics in Golestan, Imam Khomeini, and Abuzar Hospitals were betalactams (including first to fourth-generation cephalosporins and carbapenems), which accounted for 43%, 42%, and 46%, respectively. Third-generation cephalosporins were the most commonly used antibiotics in all three hospitals, accounting for 28.6%, 20%, and 32.4%, respectively. The least commonly used antibiotics included penicillins (4%), quinolones (3%), and macrolides (5%) (Figures 1-3).

The frequency of antibiotic use for communityacquired infections in Golestan, Imam Khomeini, and Abuzar Hospitals was 60 people (89.6%), 79 people (98.8%), and 105 people (90.5%), respectively. For healthcare-associated infections, there were 7 people (10.4%), 1 person (1.2%), and 11 people (9.5%), respectively (Table 2). The most common diagnoses treated with antimicrobial medicine in Golestan and Imam Khomeini Hospitals included skin and soft tissue infections [13 (38.2%) and 13 (29.5%), respectively] and sepsis [7 (20.6%) and 9 (20.5%), respectively]. In Abuzar Hospital, the most common diagnoses were pneumonia [20 (35.1%)] and lower urinary tract infections (UTIs) [12 (21.1%)]. Other results are presented in Table 2.

The most common antibiotic for sepsis in adults and children in Golestan, Imam Khomeini, and Abuzar Hospitals was vancomycin (28.5%, 22.2%, and 40%, respectively). In Golestan Hospital, ceftriaxone was used more frequently for treating gastrointestinal infections, while meropenem was used more often for upper and lower UTIs. In Imam Khomeini Hospital, meropenem was used more for pneumonia treatment, ceftriaxone and metronidazole were used for surgical prophylaxis, ceftriaxone and metronidazole for gastrointestinal infection prevention, and ceftriaxone for urinary tract infection surgical prophylaxis. In Abuzar Hospital, metronidazole and ceftriaxone were used for surgical prophylaxis and gastrointestinal infections, and ceftriaxone and amikacin were used to treat upper and lower UTIs (Table 2).

The frequency of a single-dose surgical prophylaxis in adults and children in Golestan and Imam Khomeini Hospitals was 1% and 20%, respectively. This rate was zero for upper UTIs, plastic surgery, orthopedic surgery, gastrointestinal tract infections, and central nervous system infections in adults and children in each hospital. Additionally, in Imam Khomeini Hospital, the frequency of a single dose of prophylaxis in the obstetrics and gynecology ward was reported as 5%, while in Abuzar Hospital, the single-dose frequency of

Variables and Subgroups	No. (%) or Mean ± SD		
Gender			
Male	1028 (50.51)		
Female	1007 (49.49)		
Hospital			
Imam Khomeini	839 (41.22)		
Golestan	728 (38.42)		
Abuzar	414 (20.36)		
Quantitative variable			
Age of participants	46.18 ± 8.83		

	Hospitals				
Variables and Subgroups	Golestan (N = 782)	Imam Khomeini (N = 839)	Abuzar (N = 414)		
Prevalence					
Total	338 (43.2)	370 (44.2)	216 (57.9)		
Adults	151 (31.1)	104 (27.9)	-		
Surgery ward	116 (56)	25 (52)			
ICU	71 (47.9)	187 (40.6)			
Children	19 (10.5)	60 (71.7)			
Infection					
Community-acquired	60 (89.6)	79 (98.8)	105 (90.5)		
Healthcare-associated	7(10.4)	1(1.2)	11 (9.5)		
Site					
Skin and soft tissue	13 (28.3)	13 (29.5)	2 (3.6)		
Sepsis	7(20.6)	9 (20.5)	10 (17.5)		
Nervous system	3 (8.8)	2 (4.5)	1 (1.8)		
Pneumonia	2 (5.9)	3 (6.8)	20 (35.1)		
Gastrointstinal	1(2.9)	0(0)	3 (5.3)		
Cardiovascular	3 (6.8)	3 (6.8)	0(0)		
Tuberculosis	3 (6.8)	2 (4.5)	0(0)		
Osteomyelitis	3 (6.8)	0(0)	1 (1.8)		
Upper urinary tract	0(0)	0(0)	1 (1.8)		
Lower urinary tract	0(0)	3 (6.8)	12 (21.1)		
Cystic fibrosis	0(0)	0(0)	1 (1.8)		
Prescribing of intravenous antibiotics	148 (20.3)	139 (16.5)	125 (30.1)		
Prescribing multiple antibiotics	105 (14.4)	139 (16.5)	93 (22.4)		
Type of treatment					
Experimental	273 (30.3)	263 (32.2)	22 (5.3)		
Targeted	11 (1.4)	2 (0.02)	20 (4.8)		
Type of prophylaxis					
Gastrointestinal tract infection	Ceftriaxone	Ceftriaxone/metronidazole	Ceftriaxone/metronidazole		
Urinary tract infection	Meropenem	Meropenem	Ceftriaxone/amikacin		
Pneumonia	-	Meropenem			
Surgical prophylaxis	-	Ceftriaxone/metronidazole	Ceftriaxone/metronidazole		

prophylaxis for children's surgery and gastrointestinal infections was reported as 2%. The frequency of intravenous antibiotic prescriptions for all patients in Golestan, Imam Khomeini, and Abuzar Hospitals was 148 (20.3%), 139 (16.5%), and 125 (30.1%) patients, respectively. Also, in the three hospitals, 273 (30.3%), 363 (32.3%), and 22 (5.3%) patients underwent empirical treatment, and 11 (1.4%), 2 (0.2%), and 20 (4.8%) patients underwent targeted antibiotic therapy, respectively (Table 2).

Overall antibiotic prescriptions for systemic use, according to the WHO AWaRe classification (WHO: Access, watch, reserve), in the three hospitals were 62%, 53%, and 57%, respectively, in the Watch group (the watch




Figure 1. Antibacterials for systemic use (ATC J01) at the ATC3 level (subgroup specific medicine) in Golestan Hospital. Country: Iran, continent: East and South Asia, hospital type: Tertiary hospitals




Figure 2. Antibacterials for systemic use (ATC J01) at the ATC3 level (subgroup specific medicine) in Imam Khomeini Hospital. Country: Iran, continent: East and South Asia, hospital type: Tertiary hospitals

group contains broad-spectrum antibiotics with a higher potential for developing resistance), 35%, 45%, and 41% in the Access group (the access group contains antibiotics used in the first- and second-line treatment of infections), and 2% in the reserve group (the reserve group contains last-resort antibiotics used for multidrug-resistant infections) (Figures 4 - 6).

The results related to the duration of prophylaxis are presented in Figures 7 - 9. The highest rates of antimicrobial resistance were reported for cefazolin (81.42%), ampicillin (93.77%), and ampicillin (94.02%) in Golestan, Imam Khomeini, and Abuzar Hospitals, respectively. Additionally, the lowest rates of antimicrobial resistance were reported for ciprofloxacin (18.57%) in Golestan Hospital, ciprofloxacin (15.58%) in Imam Khomeini Hospital, and piperacillin/tazobactam (12.04%) in Abuzar Hospital, respectively (Table 3).

This study analyzed bacterial infections across three hospitals based on culture results, identifying 222 confirmed cases. The most prevalent bacteria were *Streptococcus pneumoniae* (24.77%), Methicillin-Resistant *Staphylococcus aureus* (MRSA) (20.81%),




Figure 3. Antibacterials for systemic use (ATC J01) at the ATC3 level (subgroup specific medicine) in Abuzar Hospital. Country: Iran, continent: East and South Asia, hospital type: Tertiary hospitals




Figure 4. Antibacterials for systemic use (ATC J01) according to the World Health Organization (WHO) AWaRe classification in Golestan Hospital

Klebsiella pneumoniae (16.67%), Escherichia coli (13.86%), Pseudomonas aeruginosa (8.11%), Salmonella (10.36%), and *Shigella* (5.41%), respectively (Table 4).

5. Discussion



Figure 5. Antibacterials for systemic use (ATC J01) according to the World Health Organization (WHO) AWaRe classification in Imam Khomeini Hospital

For over fifty years, antibiotics have been used for the rapid and effective treatment of infections. Throughout this time, there have been many changes in the types of antibiotics available and in the sensitivity and resistance of bacteria to them. Numerous studies worldwide have been initiated to investigate the stability of microbes against antibiotics and the inefficacy of new antibiotics. The primary factor contributing to antibiotic resistance is natural selection (3, 4). This study was conducted by gathering data from three major hospitals in Ahvaz. The most commonly used antibiotics for both children and adults were third-generation cephalosporins, while quinolones and penicillins were the least utilized antibiotics.

The prevalence of antibacterial use in Golestan and Imam Khomeini Hospitals, at 43.2% and 44.1%, respectively, is consistent with findings from similar studies indicating high rates of antibiotic prescriptions (14, 15). Notably, Abuzar Hospital reported even higher usage rates, particularly in the PICU (86.1%), suggesting a critical need for effective antimicrobial treatment in severely ill children (16). However, these figures contrast with studies in developed countries, where antibiotic prescribing rates are often lower due to stringent stewardship programs. Overprescription in the pediatric population can lead to significant issues, such as antibiotic resistance and alterations in the microbiome, emphasizing the importance of implementing targeted stewardship initiatives to optimize antibiotic use and enhance patient safety (17). Addressing this issue is crucial, as inappropriate use of antimicrobials can have lasting impacts on children's health and the efficacy of available treatments (14).

In the analysis of antibiotic usage patterns at Golestan, Imam Khomeini, and Abuzar Hospitals, betalactams, including first- to fourth-generation cephalosporins and carbapenems, were found to be the most commonly used antibiotics, comprising 43%, 42%, and 46% of total prescriptions, respectively. Among these, third-generation cephalosporins accounted for 28.6%, 20%, and 32.4% of antibiotic use across the hospitals. This high reliance on beta-lactams aligns with




Figure 6. Antibacterials for systemic use (ATC [01] according to the World Health Organization (WHO) AWaRe classification in Abuzar Hospital

findings from other studies that demonstrate their effectiveness against prevalent pathogens in clinical settings (18, 19). However, the emergence of multidrugresistant strains, such as carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Shigella species, is a growing concern, as these pathogens harbor extendedspectrum beta-lactamase (ESBL) genes, significantly complicating treatment options (20). This aspect highlights a potential contradiction with the current practice observed in these hospitals; while beta-lactams are frequently prescribed, increasing resistance patterns challenge their utility as first-line treatments (18). Thus, the significant reliance on beta-lactams underscores the urgent need for antibiotic stewardship programs to address these resistance issues and optimize treatment efficacy.

The findings regarding antimicrobial resistance in Golestan, Imam Khomeini, and Abuzar Hospitals indicate alarmingly high resistance rates for cefazolin (81.42%), ampicillin (93.77%), and piperacillin (94.02%).

These statistics highlight a significant challenge in treating infections caused by common pathogens in these healthcare settings. The elevated resistance rates for beta-lactam antibiotics, such as cefazolin and ampicillin, are consistent with previous research indicating widespread resistance mechanisms, including the distribution of resistance genes among isolates, such as those found in MRSA strains (21, 22). In contrast, the lowest rates of resistance were observed for ciprofloxacin (18.57%) and piperacillin/tazobactam (12.04%), suggesting that these agents may still maintain effectiveness against certain resistant pathogens. Notably, the emergence of plasmid-mediated quinolone resistance genes in *P. aeruginosa* further complicates the resistance landscape and indicates the need for vigilant antibiotic stewardship and surveillance programs, as these resistant strains pose significant risks in clinical environments (23). Overall, the disparity in resistance emphasizes the necessity rates for targeted interventions to mitigate the impact of antimicrobial



Figure 7. Duration of prophylaxis for adults and children in Golestan Hospital

resistance and preserve the efficacy of available treatment options (22).

Soltani et al. (5) discovered that in the pediatric ward, ceftriaxone (29.2%) and vancomycin (15%) were the most commonly used antibiotics, while in the neonatal ward, ampicillin (34.7%) and cefotaxime (14.7%) were prevalent. Another study revealed that cephalosporins were most commonly used in children, while penicillins and aminoglycosides were popular in infants (24). A metaanalysis investigating the resistance of antibacterial agents to E. coli revealed the following antibiotic resistance rates: Clarithromycin 21%, metronidazole 62%, clarithromycin and metronidazole 16%, ciprofloxacin 24%, levofloxacin 18%, erythromycin 29%, furazolidone 13%, tetracycline 8%, and amoxicillin 15%. Additionally, furazolidone and the combination of clarithromycin/metronidazole exhibited higher resistance levels in children (25).


In contrast, Tabatabaei et al. studied antibiotic resistance in children with UTIs in Iran and found high resistance rates for cotrimoxazole (97%), nalidixic acid (93%), cefotaxime (77%), and amoxicillin (62%) (26). Another study reported a 12.1% resistance rate for azithromycin in adults, with sepsis being most common

in children and skin and soft tissue infections being prevalent in adults (27). The findings from Golestan and Imam Khomeini Hospitals highlight the prevalence of skin and soft tissue infections and sepsis as the most common diagnoses requiring antimicrobial treatment. This aligns with existing literature, which emphasizes the significant burden of these infections in hospital settings (28, 29), often attributed to increased rates of comorbidities and access to healthcare services. In contrast, at Abuzar Pediatric Hospital, pneumonia and lower UTIs were most prevalent, accounting for 35.1% and 21.1% of cases, respectively. This variation may reflect differences in patient demographics and the clinical focus of pediatrics compared to adult care institutions. Furthermore, the high incidence of pneumonia emphasizes the need for effective vaccination and prevention strategies in young populations to reduce the burden of respiratory infections. Overall, these results underscore the necessity for targeted antimicrobial stewardship and infection control measures tailored to the specific needs of each patient population (30).

The data regarding the frequency of single-dose surgical prophylaxis in Golestan and Imam Khomeini



Figure 8. Duration of prophylaxis for adults and children in Imam Khomeini Hospital



Hospitals reveals notable disparities between adults and children, with rates of 1% and 20%, respectively. This significant difference highlights a potential gap in preventive strategies, particularly in adult surgical practices. The absence of prophylaxis for certain infections, such as upper UTIs, plastic surgeries, orthopedic surgeries, gastrointestinal infections, and central nervous system infections, in both adult and pediatric populations indicates a need for greater awareness and adherence to established guidelines on surgical prophylaxis. Specifically, the low prophylaxis rate in the obstetrics and gynecology ward at Imam Khomeini Hospital (5%) and the 2% rate for children's surgery in Abuzar Hospital suggest an opportunity for improvement in these areas. A study in Italy showed that infants received the most antibiotics for the prophylaxis of prematurity and sepsis, with 30.2% of antibiotic prescriptions for sepsis treatment. In older children, 64.4% of antibiotics were used for infection treatment, and 35.5% were used for prophylaxis (24).

Table 3. Frequency of Antibiotic Resistance					
Culture Results	Golestan (N = 70)	Imam Khomeini Hospital (N = 76)	Abuzar Hospital (N = 83)		
Ampicillin	35 (50)	71 (93.77)	67 (94.02)		
Cefazolin	57 (81.42)	32 (43.33)	32 (38.55)		
Ciprofloxacin	13 (18.57)	12 (15.58)	14 (16.96)		
Amikacin	28 (40)	30 (39.47)	33 (39.75)		
Gentamicin	25 (35.71)	27 (35.52)	29 (34.93)		
Cotrimoxazole	18 (25.71)	25 (32.89)	21 (25.30)		
Piperacillin/tazobactam	19 (27.14)	16 (21.05)	10 (12.04)		

Culture Results	Golestan (N = 70)	Imam Khomeini Hospital (N = 76)	Abuzar Hospital (N = 83)	Total (229)
Methicillin-resistant Staphylococcus aureus	10 (14.29)	17 (22.37)	19 (22.89)	46 (20.81)
Streptococcus pneumoniae	17 (24.29)	22 (28.95)	16 (19.28)	55 (24.77)
Klebsiella	14 (20.00)	10 (13.16)	13 (15.66)	37 (16.67)
Escherichia coli	6 (8.57)	8 (10.53)	17 (20.49)	31 (13.86)
Pseudomonas aeruginosa	3 (4.29)	8 (10.53)	7 (8.43)	18 (8.11)
Salmonella	9 (12.86)	6 (7.89)	8 (9.64)	23 (10.36)
Shigella	5 (7.14)	5 (6.58)	2 (2.41)	12 (5.41)

¹ Values are expressed as No. (%).

Another study showed that infectious diseases, including UTIs (20.8%), bone and joint infections (20.4%), chronic wound skin infections (13.4%), soft tissue abscesses (13%), and gastroenteritis (10.8%), were the main reasons for antibiotic use (3). The analysis of bacterial infections across three hospitals, which confirmed 222 cases, reveals significant insights into the microbial landscape affecting patient populations. The predominance of Streptococcus pneumoniae (24.77%) and MRSA (20.81%) underscores the challenge of dealing with resistant pathogens, highlighting an urgent need for effective infection control measures and antimicrobial stewardship. Other notable pathogens, such as K. pneumoniae (16.67%) and E. coli (13.86%), further indicate the complexity of infections commonly seen in clinical settings, which can contribute to increased morbidity and healthcare costs. These findings align with global trends of rising antibiotic resistance, particularly among hospital-associated infections (13). Furthermore, the isolation of P. aeruginosa, Salmonella, and Shigella emphasizes the importance of vigilant surveillance and targeted therapeutic strategies, as these bacteria are often linked to severe infections and outbreaks. Overall, the study highlights the necessity for

treatment protocols and prevention strategies in hospital settings (5). This study had several limitations, including the

ongoing monitoring of bacterial infections to inform

impact of the COVID-19 pandemic (31) and the characteristics of the statistical population. A study with a longer duration and a more robust surveillance system is needed for continuous monitoring of antibiotic resistance. The information related to antibiotic resistance was limited due to the small number of positive cultures, which may have led to biased conclusions. It is recommended to establish specific guidelines for prescribing antibiotics for preoperative prophylaxis and post-surgical infections. Additionally, committees to monitor antibiotic use should be formed in every hospital.

5.1. Conclusions

A high level of bacterial resistance was observed for ampicillin and cefazolin antibiotics. Ceftriaxone was the most commonly used antibiotic for both children and adults. Continuous antimicrobial surveillance is essential to combat antibiotic resistance in local.

provincial, and national referral hospitals. Effective strategies must be implemented to reduce the misuse of available antibiotics. A national surveillance program is necessary to monitor resistance rates, promote the rational use of antimicrobial drugs, and implement measures to improve patient management outcomes.

Acknowledgements

The authors would like to express their gratitude to their colleagues at Golestan, Imam Khomeini, and Abuzar Hospitals, as well as the Jundishapour Faculty of Medical Sciences, for their guidance and encouragement.

Footnotes

Authors' Contribution: Study concept and design: A. Sh.; Interpretation of data: SH. A., MR. F., and F. Sh.; Drafting of the manuscript: A. Sh. and M. P.; Critical revision of the manuscript for important intellectual content: F. Sh., Sh. A., and H. Gh.

Conflict of Interests Statement: The authors declare no conflicts of interest.

Data Availability: The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Ethical Approval: This study was approved by the Ethics Committee of Jundishapur University of Ahvaz with the code IR.AJUMS.HGOLESTAN.REC.1400.129, and all participant information remained confidential.

Funding/Support: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Informed Consent: Written informed consent was obtained from the parents of the patients who participated in this study, in accordance with the 1964 Helsinki Declaration and its later amendments, or comparable ethical standards.

References

 Darby EM, Trampari E, Siasat P, Gaya MS, Alav I, Webber MA, et al. Molecular mechanisms of antibiotic resistance revisited. *Nat Rev Microbiol.* 2023;21(5):280-95. [PubMed ID: 36411397]. https://doi.org/10.1038/s41579-022-00820-y.

- Serra-Burriel M, Keys M, Campillo-Artero C, Agodi A, Barchitta M, Gikas A, et al. Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis. *PloS One*. 2020;**10**(15). e0227139.
- Cardinale M, Bourbotte-Salmon F, Scheiwe C, Boulezaz S, Ridet M, Laitselart P. Antimicrobial resistance in N'Djamena (Chad): Four-year experience of the french forward medical and surgical team engaged in the "barkhane operation". *Med Mal Infect*. 2020;50(8):665-9. [PubMed ID: 32035720]. https://doi.org/10.1016/j.medmal.2019.12.009.
- 4. Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: Results of an internet-based global point prevalence survey. *Lancet Glob Health*. 2018;6(6):e619-29. [PubMed ID: 29681513]. https://doi.org/10.1016/S2214-109X(18)30186-4.
- 5. Soltani J, Pouladfar G, Versporten A, Sharland M, Goossens H, Jafarpour Z, et al. Point prevalence survey of antimicrobial prescription and infection in pediatric and neonatal wards of two Iranian teaching hospitals. *Erciyes Med J/Erciyes Tip Dergisi*. 2019;**41**(1):25-32.
- Reardon S. Antibiotic resistance sweeping developing world: Bacteria are increasingly dodging extermination as drug availability outpaces regulation. *Nature*. 2014;**509**(7499):141-2. [PubMed ID: 24805322]. https://doi.org/10.1038/509141a.
- Church NA, McKillip JL. Antibiotic resistance crisis: Challenges and imperatives. *Biologia*. 2021;**76**(5):1535-50. https://doi.org/10.1007/s11756-021-00697-x.
- Hagedoorn NN, Borensztajn DM, Nijman R, Balode A, von Both U, Carrol ED, et al. Variation in antibiotic prescription rates in febrile children presenting to emergency departments across Europe (MOFICHE): A multicentre observational study. *PLoS Med.* 2020;**17**(8). e1003208. [PubMed ID: 32813708]. [PubMed Central ID: PMC7444592]. https://doi.org/10.1371/journal.pmed.1003208.
- Zhou Q, Si Z, Wang K, Li K, Hong W, Zhang Y, et al. Enzyme-triggered smart antimicrobial drug release systems against bacterial infections. J Control Release. 2022;352:507-26. [PubMed ID: 36341932]. https://doi.org/10.1016/j.jconrel.2022.10.038.
- Zilberberg MD, Nathanson BH, Puzniak LA, Zilberberg NWD, Shorr AF. Inappropriate empiric therapy impacts complications and hospital resource utilization differentially among different types of bacterial nosocomial pneumonia: A Cohort study, United States, 2014-2019. Crit Care Explor. 2022;4(4). e0667. [PubMed ID: 35415613]. [PubMed Central ID: PMC8994075]. https://doi.org/10.1097/CCE.000000000000667.
- Malacarne P, Rossi C, Bertolini G; GiVi T. I. Group. Antibiotic usage in intensive care units: A pharmaco-epidemiological multicentre study. *J Antimicrob Chemother*. 2004;**54**(1):221-4. [PubMed ID: 15190030]. https://doi.org/10.1093/jac/dkh299.
- Dellamonica P, Roger PM, Mousnier A, Collomb R, Bernard E, Fosse T. How to organise antibiotic prescription. *Int J Antimicrob Agents*. 2001;**18**(3):299-303. [PubMed ID: 11673048]. https://doi.org/10.1016/s0924-8579(01)00377-6.
- Versporten A, Bielicki J, Drapier N, Sharland M, Goossens H; Arpec project group. The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. J Antimicrob Chemother. 2016;71(4):1106-17. [PubMed ID: 26747104]. https://doi.org/10.1093/jac/dkv418.
- 14. Armitage R, Nellums LB. Antibiotic prescribing in general practice during COVID-19. *Lancet Infect Dis.* 2021;**21**(6). e144. [PubMed ID:

33275941]. [PubMed Central ID: PMC9761101]. https://doi.org/10.1016/S1473-3099(20)30917-8.

- King LM, Bartoces M, Fleming-Dutra KE, Roberts RM, Hicks LA. Changes in US outpatient antibiotic prescriptions from 2011-2016. *Clin Infect Dis*. 2020;**70**(3):370-7. [PubMed ID: 30882145]. [PubMed Central ID: PMC8078491]. https://doi.org/10.1093/cid/ciz225.
- Landersdorfer CB, Nation RL. Key challenges in providing effective antibiotic therapy for critically Ill patients with bacterial sepsis and septic shock. *Clin Pharmacol Ther.* 2021;**109**(4):892-904. [PubMed ID: 33570163]. https://doi.org/10.1002/cpt.2203.
- Huang LJ, Chen SJ, Hu YW, Liu CY, Wu PF, Sun SM, et al. The impact of antimicrobial stewardship program designed to shorten antibiotics use on the incidence of resistant bacterial infections and mortality. *Sci Rep.* 2022;**12**(1):913. [PubMed ID: 35042878]. [PubMed Central ID: PMC8766441]. https://doi.org/10.1038/s41598-022-04819-6.
- Saki M, Amin M, Savari M, Hashemzadeh M, Seyedian SS. Betalactamase determinants and molecular typing of carbapenemresistant classic and hypervirulent Klebsiella pneumoniae clinical isolates from southwest of Iran. *Front Microbiol.* 2022;13:1029686.
 [PubMed ID: 36406386]. [PubMed Central ID: PMC9669656]. https://doi.org/10.3389/fmicb.2022.1029686.
- Tilanus A, Drusano G. Optimizing the use of beta-lactam antibiotics in clinical practice: A test of time. *Open Forum Infect Dis.* 2023;10(7):ofad305. [PubMed ID: 37416756]. [PubMed Central ID: PMC10319623]. https://doi.org/10.1093/ofid/ofad305.
- Farajzadeh Sheikh A, Moradi Bandbal M, Saki M. Emergence of multidrug-resistant Shigella species harboring extended-spectrum beta-lactamase genes in pediatric patients with diarrhea from southwest of Iran. *Mol Biol Rep.* 2020;47(9):7097-106. [PubMed ID: 32894435]. https://doi.org/10.1007/s11033-020-05776-x.
- Ali Alghamdi B, Al-Johani I, Al-Shamrani JM, Musamed Alshamrani H, Al-Otaibi BG, Almazmomi K, et al. Antimicrobial resistance in methicillin-resistant Staphylococcus aureus. Saudi J Biol Sci. 2023;30(4):103604. [PubMed ID: 36936699]. [PubMed Central ID: PMC10018568]. https://doi.org/10.1016/j.sjbs.2023.103604.
- Khoshnood S, Shahi F, Jomehzadeh N, Montazeri EA, Saki M, Mortazavi SM, et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among methicillinresistant Staphylococcus aureus strains isolated from burn patients. *Acta Microbiol Immunol Hung.* 2019;66(3):387-98. [PubMed ID: 31096760]. https://doi.org/10.1556/030.66.2019.015.
- 23. Saki M, Farajzadeh Sheikh A, Seyed-Mohammadi S, Asareh Zadegan Dezfuli A, Shahin M, Tabasi M, et al. Occurrence of plasmid-mediated quinolone resistance genes in Pseudomonas aeruginosa strains

isolated from clinical specimens in southwest Iran: A multicentral study. *Sci Rep.* 2022;**12**(1):2296. [PubMed ID: 35145139]. [PubMed Central ID: PMC8831490]. https://doi.org/10.1038/s41598-022-06128-4.

- De Luca M, Dona D, Montagnani C, Lo Vecchio A, Romanengo M, Tagliabue C, et al. Antibiotic prescriptions and prophylaxis in Italian children. is it time to change? data from the ARPEC project. *PLoS One*. 2016;11(5). e0154662. [PubMed ID: 27182926]. [PubMed Central ID: PMC4868290]. https://doi.org/10.1371/journal.pone.0154662.
- Septimus EJ. Antimicrobial resistance: An antimicrobial/diagnostic stewardship and infection prevention approach. *Med Clin North Am.* 2018;**102**(5):819-29. [PubMed ID: 30126573]. https://doi.org/10.1016/j.mcna.2018.04.005.
- Tabatabaei A, Ahmadi K, Shabestari AN, Khosravi N, Badamchi A. Virulence genes and antimicrobial resistance pattern in Proteus mirabilis strains isolated from patients attended with urinary infections to Tertiary Hospitals, in Iran. *Afr Health Sci.* 2021;**21**(4):1677-84. [PubMed ID: 35283944]. [PubMed Central ID: PMC8889823]. https://doi.org/10.4314/ahs.v21i4.22.
- Salmeron P, Vinado B, Arando M, Alcoceba E, Romero B, Menendez B, et al. Neisseria gonorrhoeae antimicrobial resistance in Spain: A prospective multicentre study. J Antimicrob Chemother. 2021;76(6):1523-31. [PubMed ID: 33569588]. https://doi.org/10.1093/jac/dkab037.
- Markwart R, Saito H, Harder T, Tomczyk S, Cassini A, Fleischmann-Struzek C, et al. Epidemiology and burden of sepsis acquired in hospitals and intensive care units: A systematic review and metaanalysis. *Intensive Care Med.* 2020;46(8):1536-51. [PubMed ID: 32591853]. [PubMed Central ID: PMC7381455]. https://doi.org/10.1007/s00134-020-06106-2.
- 29. Hosseininasab A, Pouramini M, Ghaedamini H, Ahmadipour H, Kalantarinejad N, Farahbakhsh S, et al. [Evaluation of the clinical signs, predisposing factors, laboratory symptoms, treatment and outcome of term infants admitted in Kfzalipour Kerman Hospital with the diagnosis of early sepsis]. *Razi J Med Sci.* 2023;**30**(2). FA.
- 30. Mohammadi R, Saboori M, Tabesh H, Shafiei M, Dehghani L, Ghaedamini A, et al. [Comparing the effectiveness of vancomycin and cefazolin in preventing post craniotomy surgical site infections]. *J Isfahan Med Sch.* 2023;**41**(712):180-7. FA.
- Ghaedamini H, Jafari H, Farahbakhsh S, Arefi H, Saghafi Z. Culturalreligious approach: An effective community-based disaster management strategy for reducing the mortality and morbidity of the fourth wave of coronavirus pandemic caused by the lineage b.1.17 (the British variant) in Iran (spring 2021). *Malays J Med Sci.* 2022;**29**(1):154-6. [PubMed ID: 35283685]. [PubMed Central ID: PMC8887977]. https://doi.org/10.21315/mjms2022.29.1.16.